DCM
PTGX icon

Delpha Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Delpha Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-486
Closed -$10K – 952
2017
Q4 		$10K Buy
+486
New +$8.62K 0.01% 1078

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Delpha Capital Management's PTGX Position: Q1 2018 in Review

Delpha Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2018, closing a stake of 486 shares — an estimated $10K sold.

Delpha Capital Management first reported a position in PTGX in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 70 funds tracked by Wall St. Rank hold PTGX as of Q1 2018.

  • Delpha Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 486 Protagonist Therapeutics shares in Q1 2018, an estimated $10K.
  • Delpha Capital Management first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Protagonist Therapeutics position peaked at $10K in Q4 2017.
  • 70 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.